Legend Biotech (LEGN) Capital Expenditures (2020 - 2025)

Legend Biotech has reported Capital Expenditures for 6 years, with the latest figure at -$5.0 million in Q3 2025.

• For the quarter ending Q3 2025, Capital Expenditures fell 142.37% year-over-year to -$5.0 million; the trailing twelve-month figure through Sep 2025 stood at $9.6 million (down 60.16% YoY), and the FY2024 full-year result was $14.1 million, down 29.77% from the prior year.
• Capital Expenditures for Q3 2025 stood at -$5.0 million, up from -$9.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $35.8 million in Q4 2023, with the low at -$42.2 million in Q4 2021.
• Historically, Capital Expenditures has averaged -$5.3 million across 5 years, with a median of -$5.4 million in 2023.
• The largest YoY upside for Capital Expenditures was 271.18% in 2023 against a maximum downside of 1990.68% in 2023.
• Legend Biotech's Capital Expenditures stood at -$42.2 million in 2021, then soared by 50.41% to -$20.9 million in 2022, then surged by 271.18% to $35.8 million in 2023, then retreated by 27.89% to $25.8 million in 2024, then tumbled by 119.38% to -$5.0 million in 2025.
• The last three Capital Expenditures figures came in at -$5.0 million (Q3 2025), -$9.2 million (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.